Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Aug 21;31(2):209-19.
doi: 10.1016/j.immuni.2009.05.012. Epub 2009 Jul 30.

Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose

Margarida Saraiva  1 , Jillian R Christensen, Marc Veldhoen, Theresa L Murphy, Kenneth M Murphy, Anne O'Garra
Affiliations

Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose

Margarida Saraiva et al. Immunity. .

Abstract

CD4(+) T cells producing interleukin-10 (IL-10) and interferon-gamma (IFN-gamma) are reported in chronic infections. However, the signals that direct the development of IL-10-producing T helper 1 (Th1) cells are undefined. We showed that development of IL-10-producing Th1 cells required high T cell receptor (TCR) ligation, sustained ERK1 and ERK2 MAP kinases phosphorylation, and IL-12-induced STAT4 transcription factor activation. Repeated TCR triggering led to enhanced IL-10 production by Th1 cells, and continued IL-12 action and high-dose TCR signaling were required for the development and maintenance of IL-10-producing Th1 cells. Although Th1, Th2, and Th17 cells require the activation of distinct STATs for their differentiation, activation of ERK1 and ERK2 was a common requirement for production of IL-10 by all Th cell subsets. IL-10 expression also correlated with c-maf expression. Despite having distinct functions in protection against pathogens, all Th cells share the important task of controlling overexuberant immune responses by means of IL-10 production.

PubMed Disclaimer

Figures

Figure 1
Figure 1
IL-12 Enhances IL-10 Production at High Antigen Dose Only Naive CD4+ T cells from DO11.10 TCR transgenic animals were isolated and differentiated for 1 week with splenic DCs in medium containing increasing doses of OVA in the absence (medium) or presence of IL-12, as indicated. On day 7, cells were restimulated for 4 hr with plate-bound anti-CD3 and soluble anti-CD28 and BrefeldinA and (A) stained at the single-cell level for IL-10, IFN-γ, and IL-4, or (B) stimulated similarly for 48 hr in the absence of BrefeldinA, and the culture supernatants analyzed by ELISA. Data are representative of six experiments performed; error bars in (B) refer to the standard deviation of three independent cultures.
Figure 2
Figure 2
IL-10 Production by Th1 Cells Requires IL-12-Induced STAT4 Activation CD4+ T cells from DO11.10 animals on a (A, B, and C) WT, Stat4−/−, or Stat6−/− background, (D) Ifnγ−/− background, or (E and F) Il4−/− background were isolated and differentiated as in Figure 1. As shown in (B), Th2-driven cells were differentiated for 1 week in medium containing IL-4 (10 ng/ml) and anti-IL-12 (10 μg/ml) plus 1 μM OVA; or (C and F) 0.05 μM OVA alone (low-antigen-dose-driven Th2 cells). On day 7, cells were restimulated and IL-10, IFN-γ, and IL-4 production were detected by ICS or by immunoassay as in Figure 1. Represented is one of three experiments performed. Detection of cytokines by ELISA in the supernatants of cultures restimulated for 48 hr (data not shown) confirmed the results observed for ICS in (A) and (B). Error bars refer to the standard deviation of replicate values of three independent cultures.
Figure 3
Figure 3
In Vivo Generation of IL-10-Producing Th1 Cells Requires High Antigen Dose, Innate Immune Signals and STAT4 (A) Spleen cell suspensions from DO11.10 animals were injected into BALB/c recipients. Cells were isolated from the inguinal lymph nodes of mice injected with PBS, OVA protein (5 mg) plus or minus LPS (5 μg) and restimulated in vitro with OVA for 48 hr. IL-10 and IFN-γ production was analyzed by ELISA. Represented is the mean ± SD of groups of three animals each. Spleen cell suspensions from DO11.10 WT (ten animals), Stat4−/− (nine animals), or Stat6−/− (ten animals) were transferred into BALB/c recipients, which were then injected with OVA protein and LPS (5 mg and 5 μg, respectively). Cells recovered as above were restimulated in vitro, for 24–48 hr with the last 6 hr in the presence (for ICS, B) or absence (for ELISA, C) of BrefeldinA. IL-10 and IFN-γ expression was detected by ICS and represented within the CD4+ KJ1-26+ T cells population. (B) We obtained the plots represented by merging the plots from each mouse within one group. Two independent experiments confirmed the result showed and the mean percentage of IL-10/IFN-γ producers ± SD was 3.95 ± 1.15 and 2.25 ± 0.68; 4.29 ± 1.36 and 7.11 ± 1.86; and 3.82 ± 0.96 and 10.19 ± 2.25 for DO11.10 WT, Stat4−/−, and Stat6−/−, respectively. (C) Error bars refer to the standard deviation of replicate values on two independent experiments.
Figure 4
Figure 4
High Antigen Dose and IL-12 Are Required for Maximal Production of IL-10 by Th1 Cells CD4+ T cells from DO11.10 TCR transgenic animals were cultured for 1 week with a high (0.7 μM) dose of OVA and DC in the (A and B) presence or (C) absence of IL-12 and subsequently washed, counted, and recultured with a high (0.7 μM; B, D, and E) or low (0.01 μM; F) dose of OVA and DC in the absence or presence of IL-12 as indicated. CD4+ T cells from DO11.10 TCR transgenic animals were cultured with a high (0.7 μM) dose of OVA and WT or Il12b−/− DCs in the absence of added IL-12 for 2 weeks (E). At the end of the first (A, C, and E) and the second week (B, D, E, and F), cells were restimulated with anti-CD3 and anti-CD28, and IFN-γ and IL-10 cytokine expression were detected by ICS. Represented is one of three experiments performed.
Figure 5
Figure 5
IL-10 Production by Th1, Th2, and Th17 Cells Requires ERK1 and ERK2 Activation CD4+ T cells from DO11.10 TCR transgenic animals were cultured with a high (0.7 μM) or low (0.01 μM) dose of OVA and DC in the absence or presence of IL-12. On day 3, cells were harvested, rested for 5 hr in low (1%) serum medium, and restimulated with high (0.7 μM) or low (0.01 μM) antigen dose, in the (A and B) absence or in the (B) presence of IL-12, for the indicated time points. Cellular lysates were prepared, proteins were separated by SDS-PAGE, and phospho(p)- or total(t)-ERK1 and ERK2 were detected by immunoblotting. Actin was included as a loading control (A and B). CD4+ T cells from BALB/c animals were isolated and cultured for 7 days in the presence of increasing doses of plate-bound anti-CD3, soluble anti-CD28, and IL-12 (3 ng/ml), in the absence (control, with DMSO) or presence of U0126 (2.5 μM) (MEK Inhibitor). As shown in (C), on day 7, cells were restimulated as above and the expression of IL-10 and IFN-γ was detected by ICS. Cytokine production in the supernatants of 48 hr restimulated cultures was analyzed by ELISA and confirmed the ICS results (data not shown). As shown in (D), CD4+ T cells from BALB/c animals were isolated and cultured for 5 days in the presence of plate-bound anti-CD3, soluble anti-CD28 and one of the following combinations: IL-12 (3 ng/ml) plus anti-IL-4 (20 μg/ml), for Th1; IL-4 (10 ng/ml) plus anti-IL-12 (10 μg/ml), for Th2; or IL-6 (50 ng/ml), TGF-β (1 ng/ml) and IL-1 (10 ng/ml), for Th17, all in the absence (control, with DMSO) or presence of PD184352 MEK Inhibitor, as in (C). On day 5, cells were restimulated with PdBU and ionomycin, and the expression of IL-10, IFN-γ, IL-4, and IL-17 was detected by ICS. Represented is one of three (A, B, C, and F) or one of four (D and E) experiments performed.
Figure 6
Figure 6
c-maf Is Expressed in IL-10-Producing Th1, Th2, and Th17 Cells CD4+ T cells from DO11.10 TCR transgenic animals were differentiated for 1 week in medium containing increasing doses of OVA plus DC in the absence (Med) or presence of IL-12, as indicated. On day 7, cells were (A) restimulated for cytokine expression or (B) not restimulated for transcription factor expression as in Figure 1. CD4+ T cells from C57Bl/6 animals were isolated and cultured for 5 days in the presence of plate-bound anti-CD3 (50 ng/ml), soluble anti-CD28 (50 ng/ml), IL-6 (50 ng/ml), TGF-β (1 ng/ml), and IL-1 (10 ng/ml); Th17 cells were restimulated on day 5 (for cytokine expression) or not (for transcription factor expression) as in Figure 5C. Th1 and Th17 cells were cultured as in Figure, all in the absence (−; Control), with DMSO, or presence (+) of the PD184352 MEK inhibitor. Transcription factor expression is shown in (D). Similar results were obtained from three (A, B, and C) or two experiments (D, with two doses of inhibitor or control). Cytokine and transcription factor expression were analyzed from RNA isolated from all populations by RT real-time PCR.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Agrawal A., Dillon S., Denning T.L., Pulendran B. ERK1−/− mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis. J. Immunol. 2006;176:5788–5796. - PubMed
    1. Anderson C.F., Oukka M., Kuchroo V.J., Sacks D. CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J. Exp. Med. 2007;204:285–297. - PMC - PubMed
    1. Assenmacher M., Schmitz J., Radbruch A. Flow cytometric determination of cytokines in activated murine T helper lymphocytes: Expression of interleukin-10 in interferon-gamma and in interleukin-4-expressing cells. Eur. J. Immunol. 1994;24:1097–1101. - PubMed
    1. Awasthi A., Carrier Y., Peron J.P., Bettelli E., Kamanaka M., Flavell R.A., Kuchroo V.K., Oukka M., Weiner H.L. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 2007;8:1380–1389. - PubMed
    1. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., Cohen P. The selectivity of protein kinase inhibitors: A further update. Biochem. J. 2007;408:297–315. - PMC - PubMed

Publication types

MeSH terms